Advertisement

Journal of Gastrointestinal Cancer

, Volume 41, Issue 4, pp 272–274 | Cite as

Rapidly Progressing Malignant Insulinoma Presented with Multiple Liver Metastases: A Case Report

  • Erdogan Askin
  • Kose FatihEmail author
  • Akkaya Hampar
  • Neslihan Bascil Tutuncu
  • Ozyilkan Ozgur
Brief Communication

Abstract

Introduction

A 51-year-old female was admitted to emergency unit with sudden loss of consciousness. Her blood glucose level from fingertip was 33 mg/dl, and insulin level was 55 (normal range, 4–17 IU). Abdominal ultrasonography revealed pancreatic mass with diffuse liver metastases. Biopsy of liver metastases showed differentiated neuroendocrine carcinoma.

Methods and Results

Diazoxide and chemotherapy stabilized her glucose level for more than 4 months. However, the disease showed progression, and death occurred 8 months later.

Conclusion

In conclusion, this case may suggest that biologic behavior may differ from histological behavior in insulinoma and platin-based systemic chemotherapy may provide some benefit in patients those who had diazoxide- and octreotide-resistant tumors.

Keywords

malignant insulinoma diazoxide chemotherapy rapidly progressing 

References

  1. 1.
    Service FJ, McMahon MM, O'Brien PC, Ballard DJ. Functioning insulinoma-incidence, recurrence and long-term survival of patients: a 60-year study. Mayo Clin Proc. 1991;66:711.PubMedGoogle Scholar
  2. 2.
    Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER, et al. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2009;94:709–28.CrossRefPubMedGoogle Scholar
  3. 3.
    Kloppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann NY Acad Sci. 2004;1014:13–27.CrossRefPubMedGoogle Scholar
  4. 4.
    Musunuru S, Chen H, Rajpal S, Stephani N, McDermott JC, Holen K, et al. Metastatic neuroendocrine hepatic tumors: resection improves survival. Arch Surg. 2006;141:1000–4.CrossRefPubMedGoogle Scholar
  5. 5.
    Abood GJ, Go A, Malhotra D, Shoup M. The surgical and systemic management of neuroendocrine tumors of the pancreas. Surg Clin North Am. 2009;89:249–66.CrossRefPubMedGoogle Scholar
  6. 6.
    Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005;104:1590–602.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Erdogan Askin
    • 1
  • Kose Fatih
    • 2
    • 5
    Email author
  • Akkaya Hampar
    • 3
  • Neslihan Bascil Tutuncu
    • 4
  • Ozyilkan Ozgur
    • 2
  1. 1.Departments of GastroenterologyBaskent UniversityAnkaraTurkey
  2. 2.Department of Medical OncologyBaskent UniversityAnkaraTurkey
  3. 3.Department of PathologyBaskent UniversityAnkaraTurkey
  4. 4.EndocrinologyBaskent UniversityAnkaraTurkey
  5. 5.Adana Teaching and Medical Research CenterBaskent UniversityAdanaTurkey

Personalised recommendations